Molecular Markers of Chemotherapy Toxicity in Colorectal Cancer

被引：2
|
作者：
Braun, Michael S. [1 ]
Seymour, Matthew T. [1 ]
机构：
[1] Univ Leeds, Leeds Inst Mol Med, Sect Oncol & Clin Res, Leeds, W Yorkshire, England
来源：
CURRENT COLORECTAL CANCER REPORTS | 2011年 / 7卷 / 01期
关键词：
Fluorouracil; Irinotecan; Oxaliplatin; Pharmacogenomics; Toxicity; Colorectal;
D O I：
10.1007/s11888-010-0078-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Personalized medicine appears to be the inevitable consequence of improvements in our understanding of the mechanisms of action of chemotherapeutic agents, as well as the description of the human genome and its impact on our understanding of the genes involved in DNA repair and drug metabolism. These rapid developments have been associated with the first efforts to establish genetic predictors of chemotherapy efficacy and toxicity for the chemotherapy drugs active in colorectal cancer-fluorouracil, irinotecan, and oxaliplatin.
引用
收藏
页码：105 / 111
页数：7
相关论文
共 50 条
  • [1] Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
    Chua, W.
    Goldstein, D.
    Lee, C. K.
    Dhillon, H.
    Michael, M.
    Mitchell, P.
    Clarke, S. J.
    Iacopetta, B.
    BRITISH JOURNAL OF CANCER, 2009, 101 (06) : 998 - 1004
  • [2] Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
    W Chua
    D Goldstein
    C K Lee
    H Dhillon
    M Michael
    P Mitchell
    S J Clarke
    B Iacopetta
    British Journal of Cancer, 2009, 101 : 998 - 1004
  • [3] Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients
    Cortejoso, Lucia
    Lopez-Fernandez, Luis A.
    PHARMACOGENOMICS, 2012, 13 (10) : 1173 - 1191
  • [4] Molecular Markers of Chemotherapy Response in Colorectal Cancer
    Braun, Michael S.
    Seymour, Matthew T.
    CURRENT COLORECTAL CANCER REPORTS, 2010, 6 (03) : 118 - 125
  • [5] Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer (FOCUS).
    Seymour, M. T.
    Braun, M. S.
    Richman, S. D.
    Daly, C.
    Thompson, L. C.
    Meade, A.
    Parmar, M.
    Allan, J. M.
    Selby, P.
    Quirke, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 84S - 84S
  • [6] Molecular markers of chemotherapeutic response and toxicity in colorectal cancer
    Braun, Michael S.
    Quirke, Philip
    Seymour, Matthew T.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) : 489 - 501
  • [7] Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer
    Shiovitz S.
    Grady W.M.
    Current Gastroenterology Reports, 2015, 17 (2)
  • [8] Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial
    Braun, Michael S.
    Richman, Susan D.
    Thompson, Lindsay
    Daly, Catherine L.
    Meade, Angela M.
    Adlard, Julian W.
    Allan, James M.
    Parmar, Mahesh K. B.
    Quirke, Philip
    Seymour, Matthew T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5519 - 5528
  • [9] Molecular markers of chemotherapy in advanced colorectal cancer: Back to square one
    Sobrero, Alberto
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) : 1902 - 1903
  • [10] Molecular Markers for Colorectal Cancer
    Wright, Moriah
    Beaty, Jenifer S.
    Ternent, Charles A.
    SURGICAL CLINICS OF NORTH AMERICA, 2017, 97 (03) : 683 - +
12345